Filtered By:
Education: Study
Vaccination: Meningitis Vaccine
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Evaluating Clinical Effectiveness of Pneumococcal Vaccination in Preventing Stroke: The CAPAMIS Study, 3-Year Follow-up
This study assessed clinical effectiveness of PPV23 in preventing ischemic stroke in people older than 60 years.Methods: We conducted a population-based cohort study involving 27,204 individuals of 60 years or older in Tarragona, Spain, who were prospectively followed from December 01, 2008, until November 30, 2011. Outcomes were neuroimaging-confirmed ischemic stroke, 30-day mortality from stroke, and all-cause death. Pneumococcal vaccination effectiveness was evaluated by Cox regression analyses, estimating hazard ratios (HRs) adjusted for age, sex, comorbidities, and influenza vaccine status.Results: Cohort members were...
Source: Journal of Stroke and Cerebrovascular Diseases - March 21, 2014 Category: Neurology Authors: Angel Vila-Corcoles, Olga Ochoa-Gondar, Teresa Rodriguez-Blanco, Cinta de Diego-Cabanes, Eva Satue-Gracia, Angel Vila-Rovira, Cristina Torrente Fraga, EPIVAC Research Group Tags: Original Articles Source Type: research
Flu jab "may cut" stroke risk by a quarter
ConclusionThis research finds that, overall, having the flu vaccine reduced the risk of a person experiencing a stroke by about 25%. The reduction in risk seemed to be greatest within the first three months of vaccination, but remained for up to 12 months. However, the effect lasted only if the vaccine was given early in the flu season (September to mid-November); giving the vaccine late in the flu season (mid-November to February) was not associated with significantly reduced risk.The research benefits from using data coded within the General Practice Research Database for England and Wales for almost 50,000 people with...
Source: NHS News Feed - February 21, 2014 Category: Consumer Health News Tags: Heart/lungs Neurology Older people Source Type: news
Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-Matched case control study.
CONCLUSIONS: Influenza vaccination was associated with a 24% reduction in risk of stroke but not TIA. Pneumococcal vaccination was not associated with reduced risk of stroke or TIA. This has important implications for potential benefits of influenza vaccine.
PMID: 24486370 [PubMed - as supplied by publisher]
Source: Vaccine - January 28, 2014 Category: Allergy & Immunology Authors: Siriwardena AN, Asghar Z, Coupland CA Tags: Vaccine Source Type: research
Influenza Vaccination and Risk of Ischemic Stroke: A Population-Based Case-Control Study
DISCUSSION: Results are compatible with a moderate protective effect of influenza vaccine on IS appearing early after vaccination. The finding that a reduced risk was also observed in pre-epidemic periods suggests that either the "protection" is not totally linked to prevention of influenza infection, or it may be partly explained by unmeasured confounding factors.PMID:36240087 | DOI:10.1212/WNL.0000000000201123
Source: Cancer Control - October 14, 2022 Category: Cancer & Oncology Authors: Sara Rodr íguez-Martín Diana Barreira-Hern ández Miguel Gil Alberto Garc ía-Lledó Laura Izquierdo-Esteban Francisco Jose De Abajo Source Type: research
Evaluating Clinical Effectiveness of Pneumococcal Vaccination in Preventing Stroke: The CAPAMIS Study, 3-Year Follow-up
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2014 Category: Neurology Authors: Angel Vila-Corcoles, Olga Ochoa-Gondar, Teresa Rodriguez-Blanco, Cinta de Diego-Cabanes, Eva Satue-Gracia, Angel Vila-Rovira, Cristina Torrente Fraga, EPIVAC Research Group Tags: Original Articles Source Type: research
Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure
Influenza and pneumococcal infections have been suggested to be potential risk factors for causing adverse cardiovascular events, especially in high-risk patients. Vaccination against respiratory infections in patients with established cardiovascular disease (CVD) could serve as a potential cost-effective intervention to improve their clinical outcomes and cardiac societies have encouraged it. Previous studies have shown that influenza vaccination reduce mortality, acute coronary syndromes and hospitalization in patients with coronary heart disease (CHD) and/or heart failure (HF). However, there is a paucity of randomized ...
Source: Cardiology - November 15, 2018 Category: Cardiology Source Type: research
Relative Burden of Community-Acquired Pneumonia Hospitalizations in Seniors
Conclusions Although CAP has a higher burden of hospitalization and total costs than MI, stroke, and OF in the elderly population, prevention efforts are much smaller for CAP. Prioritization of CAP prevention is needed to substantially reduce its burden.
Source: American Journal of Preventive Medicine - July 12, 2016 Category: Global & Universal Source Type: research
Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study
This study aimed to investigate the protective effect of PPSV23 on cardiovascular events in adults aged ≥ 65 years. This population-based nested case-control study was conducted using the claims data and vaccine records between April 2015 and March 2020 from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. PPSV23 vaccination was identified using vaccination records in each municipality. The primary outcome was acute myocardial infarction (AMI) or stroke. The adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for PPSV23 vaccination were calculated using conditional logistic regressio...
Source: Vaccine - March 4, 2023 Category: Allergy & Immunology Authors: Nobuhiro Narii Tetsuhisa Kitamura Sho Komukai Ling Zha Masayo Komatsu Fumiko Murata Megumi Maeda Kosuke Kiyohara Tomotaka Sobue Haruhisa Fukuda Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Central Nervous System Complications of Varicella-Zoster Virus
Conclusion: Neurologic complications of VZV infection continue to occur despite the availability of an effective vaccine. Neurologic symptom onset can predate the appearance of the VZV exanthem and in rare cases may occur in the absence of an exanthem.
Source: The Journal of Pediatrics - July 24, 2014 Category: Pediatrics Authors: Michelle Science, Daune MacGregor, Susan E. Richardson, Sanjay Mahant, Dat Tran, Ari Bitnun Tags: Original Articles Source Type: research
Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study.
CONCLUSIONS: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events.
PMID: 32046891 [PubMed - as supplied by publisher]
Source: Vaccine - February 7, 2020 Category: Allergy & Immunology Authors: Liu CH, Yeh YC, Huang WT, Chie WC, Chan KA Tags: Vaccine Source Type: research
Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review
Geroscience. 2023 Jun 3. doi: 10.1007/s11357-023-00807-4. Online ahead of print.ABSTRACTThis systematic review aims to summarize the impact of vaccination against influenza, shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the elderly. This protocol was developed in accordance with PRISMA guidelines. We conducted a literature search and identified all relevant articles published regarding the matter up to September 2022. We retrieved 38 studies (influenza vaccine = 33, pneumococcal vaccine = 5, and zoster vaccine = 2). A total of 28 and 2 studies have shown that influenza and pneumococcal...
Source: Herpes - June 3, 2023 Category: Infectious Diseases Authors: Alexandra Addario Thomas C élarier Bienvenu Bongue Nathalie Barth Ga ëtan Gavazzi Elisabeth Botelho-Nevers Source Type: research
